Related references
Note: Only part of the references are listed.Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors
Hiu-yan Chan et al.
ADVANCES IN THERAPY (2010)
The mTOR Pathway: A New Target in Cancer Therapy
L. Ciuffreda et al.
CURRENT CANCER DRUG TARGETS (2010)
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
Luc Furic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Ryan J. O. Dowling et al.
SCIENCE (2010)
Not all substrates are treated equally Implications for mTOR, rapamycin-resistance and cancer therapy
Andrew Y. Choo et al.
CELL CYCLE (2009)
Novel Translational Control in Arc-dependent Long Term Potentiation Consolidation in Vivo
Debabrata Panja et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Temsirolimus in Mantle Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes
Georg Hess et al.
SEMINARS IN ONCOLOGY (2009)
Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth
James J. Gibbons et al.
SEMINARS IN ONCOLOGY (2009)
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
David T. Teachey et al.
BLOOD (2008)
MNK, EIF4E and targeting translation for therapy
Ricardo L. A. Silva et al.
CELL CYCLE (2008)
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance
Min Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Mycosis fungoides and Sezary syndrome
Sam T. Hwang et al.
LANCET (2008)
IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes
Michal Marzec et al.
BLOOD (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
DN Franz et al.
ANNALS OF NEUROLOGY (2006)
Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus
JS Zaltzman et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
G Stallone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma
JM Campistol et al.
TRANSPLANTATION (2004)
Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development
T Ueda et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma
C Jiménez-Rivera et al.
PEDIATRIC TRANSPLANTATION (2004)
Share Paper
